Abstract:Purpose: To explore the genomic profiles of Chinese patients with castration sensitive prostate cancer and those with metastatic castration resistant prostate cancer via germline and circulating tumor DNA sequencing. Materials and Methods: A hybridization capture based next-generation sequencing assay was used to identify germline and somatic alterations in 50 genes including androgen receptor pathway genes, DNA damage repair pathway genes, TP53 and RB1. Results: We successfully sequenced DNA from 396 blood samples and 32 matched tumor tissue samples from 396 patients. We observed a similar frequency of deleterious germline alterations between patients with castration sensitive prostate cancer and metastatic castration resistant prostate cancer (8.9% vs 9.8%, p>0.05). There was a high consistency (90.9%) between metastatic tumor tissue and matched circulating tumor DNA. Among patients who were circulating tumor DNA positive we observed significantly higher alteration frequencies of CDK12 (27.2% vs 6.4%, p<0.001) and FOXA1 (36.8% vs 15.3%, p<0.001) in our metastatic castration resistant prostate cancer cohort compared with the SU2C-PCF (Stand Up to Cancer-Prostate Cancer Foundation) cohort. Alteration frequencies of DNA damage repair pathway genes (66.7% vs 41.5%, p=0.015) and androgen receptor pathway genes (71.9% vs 48.8%, p=0.018) in patients with metastatic castration resistant prostate cancer were higher than in patients with de novo metastatic castration sensitive prostate cancer. Androgen receptor alteration was selectively enriched in metastatic castration resistant prostate cancer. Conclusions: Through genomic profiling of prostate cancer across clinical states we identified a similar frequency of deleterious germline alterations between patients with castration sensitive prostate cancer and metastatic castration resistant prostate cancer. We explored the genomic diversity of androgen receptor and DNA damage repair pathway genes between patients with metastatic castration sensitive prostate cancer and metastatic castration resistant prostate cancer. Higher alteration frequencies of CDK12 and FOXA1 were observed in our metastatic castration resistant prostate cancer cohort than in the SU2C-PCF cohort. Our findings support the view that circulating tumor DNA sequencing could guide clinical treatment for metastatic prostate cancer.

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Figures 1-2, Tables 1-8 from Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer

Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1 from Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance Via CaM/CaMKK–Mediated Phosphorylation of Akt

Abstract B026: Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary File 1 from Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Supplementary Table 4 from Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer

Supplementary Table 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis Via Protrusion Formation

Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing

Table S1 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer

Supplementary Data 3 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Circulating Tumor DNA-targeted Sequencing to Reveal Germline and Somatic Alterations That Can Guide Decision-Making in Metastatic Castration-Resistant Prostate Cancer.

Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets.